Blueprint Medicines Corporation Revised revenue guidance for the full year 2024. For the year, company now anticipates approximately $390 million to $410 million in global AYVAKIT net product revenues for all approved indications in 2024, an increase from the previous range of $360 million to $390 million. This updated guidance reflects continued execution in the global launch for ISM, as well as a stronger than anticipated first quarter.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
103.1 USD | -1.65% | +0.60% | +11.64% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.64% | 6.56B | |
+44.21% | 56.65B | |
-6.89% | 39.44B | |
+39.24% | 39.03B | |
-11.17% | 26.86B | |
+12.60% | 26.75B | |
-21.92% | 19.03B | |
+1.41% | 12.28B | |
+24.40% | 12.26B | |
+27.51% | 12.04B |
- Stock Market
- Equities
- BPMC Stock
- News Blueprint Medicines Corporation
- Blueprint Medicines Corporation Revises Revenue Guidance for the Full Year 2024